KWAR 23|cas:2243227-60-1|西域试剂

KWAR 23,99.80%

产品编号：Bellancom-P99175| CAS NO：2243227-60-1

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99175		￥6200.00	杭州北京（现货）
Bellancom-P99175		￥13800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

KWAR 23

产品介绍

KWAR23 是一种 anti-human SIRPα 抗体。KWAR23 以高亲和力结合 human SIRPα，并破坏其与 CD47 的结合。KWAR23 与 tumor-opsonizing 抗体联合使用具有抗肿瘤活性，可用于研究癌症免疫疗法。

生物活性

KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

体外研究

KWAR 23 (0-1 μM; 4 h) shows antitumor activity of human neutrophil and macrophage.
KWAR 23 induces human macrophage-dependent phagocytosis in human tumor-derived cell lines.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Human macrophages and lymphoma cells
Concentration:	0-1 μM
Incubation Time:	4 h
Result:	Showed human macrophages and neutrophils killing tumor cells following treatment with KWAR23.

体内研究
(In Vivo)

KWAR23 (intraperitoneal injection; 10 mg/kg; every other day; 21 d) exhibits effective antitumor activity in a human SIRPA knockin mouse model.
KWAR23 enhances neutrophil and macrophage antitumor activity in SRG Mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SIRPA knock-in mouse model injected with Burkitt’s lymphoma cells
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; 10 mg/kg; every other day; 21 d
Result:	Led to strong inhibition of tumor growth when combined with Rituximab.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SIRPA knock-in mouse model injected with Burkitt’s lymphoma cells
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; 10 mg/kg; every other day; 21 d
Result:	Led to strong inhibition of tumor growth when combined with Rituximab.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SIRPA knock-in mouse model injected with Burkitt’s lymphoma cells
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; 10 mg/kg; every other day; 21 d
Result:	Led to strong inhibition of tumor growth when combined with Rituximab.